Details for New Drug Application (NDA): 202292
The generic ingredient in MYTESI is crofelemer. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the crofelemer profile page.
Summary for 202292
| Tradename: | MYTESI |
| Applicant: | Napo Pharms Inc |
| Ingredient: | crofelemer |
| Patents: | 2 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 202292
Generic Entry Date for 202292*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, DELAYED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 202292
Suppliers and Packaging for NDA: 202292
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| MYTESI | crofelemer | TABLET, DELAYED RELEASE;ORAL | 202292 | NDA | Napo Pharmaceuticals, Inc. | 70564-802 | 70564-802-60 | 60 TABLET, COATED in 1 BOTTLE (70564-802-60) |
| MYTESI | crofelemer | TABLET, DELAYED RELEASE;ORAL | 202292 | NDA | Napo Pharmaceuticals, Inc. | 70564-802 | 70564-802-99 | 60 TABLET, COATED in 1 BOTTLE (70564-802-99) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, DELAYED RELEASE;ORAL | Strength | 125MG | ||||
| Approval Date: | Dec 31, 2012 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Oct 31, 2031 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Oct 31, 2031 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA | ||||||||
Expired US Patents for NDA 202292
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Napo Pharms Inc | MYTESI | crofelemer | TABLET, DELAYED RELEASE;ORAL | 202292-001 | Dec 31, 2012 | ⤷ Start Trial | ⤷ Start Trial |
| Napo Pharms Inc | MYTESI | crofelemer | TABLET, DELAYED RELEASE;ORAL | 202292-001 | Dec 31, 2012 | ⤷ Start Trial | ⤷ Start Trial |
| Napo Pharms Inc | MYTESI | crofelemer | TABLET, DELAYED RELEASE;ORAL | 202292-001 | Dec 31, 2012 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
